Skip to content

A Multidimensional Efficacy Evaluation of the Speaking Valve in Post-Stroke Tracheotomized Patients with Dysphagia Based on Central-Peripheral Bidirectional Closed-Loop Regulation

A Multidimensional Efficacy Evaluation of the Speaking Valve in Post-Stroke Tracheotomized Patients with Dysphagia Based on Central-Peripheral Bidirectional Closed-Loop Regulation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500110595
Enrollment
Unknown
Registered
2025-10-16
Start date
2025-10-20
Completion date
Unknown
Last updated
2025-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

Speaking Valve Group:Conventional Rehabilitation + Speaking Valve Training
Closed-Loop Regulation Group:Conventional Rehabilitation + Speaking Valve Training + Central Activation by tDCS - Peripheral Muscle Activation by NMES

Sponsors

Hebei General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1 Patients with a first-time diagnosis of acute or subacute stroke, confirmed by computed tomography (CT) or magnetic resonance imaging (MRI). 2 Aged between 18 and 80 years. 3 Patients with a clear medical history of tracheostomy, who are in a stable postoperative condition. 4 Presence of moderate to severe dysphagia confirmed by Fiberoptic Endoscopic Evaluation of Swallowing (FEES) or Videofluoroscopic Swallowing Study (VFSS). 5 Conscious and able to cooperate (GCS>=9). 6 Tolerates speaking valve training for at least 5 minutes without significant respiratory distress, as assessed by a bedside evaluation. 7 Provides signed informed consent by the subject or their legally authorized representative.

Exclusion criteria

Exclusion criteria: 1 Presence of severe cognitive impairment or coma. 2 Active respiratory instability, defined as a respiratory rate>30 breaths per minute, oxygen saturation (SpO2)<92% despite supplemental oxygen, or current requirement for mechanical ventilation. 3 History of recent aspiration pneumonia. 4 Significant structural abnormalities of the larynx. 5 Presence of a cardiac pacemaker or a known history of epilepsy. 6 Pre-existing severe psychiatric disorder. 7 Concurrent participation in any other clinical trial.

Design outcomes

Primary

MeasureTime frame
Fiberoptic Endoscopic Evaluation of Swallowing (FEES);Maximal expiratory pressure,(MEP);Maximal inspiratory pressure(MIP);Videofluoroscopic Swallow Study(VFSS);Penetration Aspiration Scale(PAS);

Secondary

MeasureTime frame
Functional Oral Intake Scale(FOIS);Semiquantitative cough strength score(SCSS);Maximum Phonation Time,(MPT);Mann assessment of swallowing ability(MASA);Wallowing Quality-of-Life Questionnaire()SWAL-QOL);Maximum Decibel(dB);

Countries

China

Contacts

Public ContactWang Yanan

Hebei General Hospital

1457857610@qq.com+86 155 3050 9083

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026